Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Other Accumulated Expenses: 2011-2025

Historic Other Accumulated Expenses for Anika Therapeutics (ANIK) over the last 12 years, with Sep 2025 value amounting to $750,000.

  • Anika Therapeutics' Other Accumulated Expenses rose 98.41% to $750,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $750,000, marking a year-over-year increase of 98.41%. This contributed to the annual value of $765,000 for FY2024, which is 126.33% up from last year.
  • Anika Therapeutics' Other Accumulated Expenses amounted to $750,000 in Q3 2025, which was up 17.00% from $641,000 recorded in Q2 2025.
  • Anika Therapeutics' Other Accumulated Expenses' 5-year high stood at $17.3 million during Q3 2021, with a 5-year trough of $338,000 in Q4 2023.
  • For the 3-year period, Anika Therapeutics' Other Accumulated Expenses averaged around $570,182, with its median value being $542,000 (2023).
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first soared by 1,581.77% in 2021, then tumbled by 97.14% in 2022.
  • Anika Therapeutics' Other Accumulated Expenses (Quarterly) stood at $1.1 million in 2021, then plummeted by 51.84% to $510,000 in 2022, then crashed by 33.73% to $338,000 in 2023, then surged by 126.33% to $765,000 in 2024, then skyrocketed by 98.41% to $750,000 in 2025.
  • Its Other Accumulated Expenses was $750,000 in Q3 2025, compared to $641,000 in Q2 2025 and $776,000 in Q1 2025.